Genovis signs agreement with QED Bioscience for distribution of the protein products

Genovis is marketing products to modify antibodies (Antibody Engineering). In order to strengthen the positioning of the products, the company has entered an agreement with QED Bioscience Inc., a company with more than 20 years of experience in the designing and manufacturing of antibodies.

The agreement means that QED Bioscience, www.qedbio.com, will sell all products for the modification of antibodies (Antibody Tools) in the US and through its 17 distributors in Europe and Asia, which will give Genovis a stable platform to increase visibility and customer contacts. QED is located in California (San Diego), USA, which is the single most important market for Antibody Engineering in preclinical research. - The Genovis protein products are derived from enzymes that make up efficient tools for the modification of antibodies. QED Bioscience has customers that in one way or the other have antibodies as a focus for their activities; be it for research, diagnostics or drug development, this is a group of customers that we are very eager to reach. I look forward to working with the experienced and competent team at QED Bioscience, with the aim to increase global sales of our unique protein products, says Sarah Fredriksson, CEO Genovis. QED Bioscience develops new antibody-based products for academia and for the biotech, diagnostic and pharmaceutical industry. The company produces and markets more than 1500 different antibodies. The manufacturing follows cGMP and in addition to catalogue products, QED Bioscience offers a variety of services to help customers design and develop completely new antibodies as well as produce and modify them according to specific customer requirements. - QED Bioscience is proud to have been selected as a distributor for Genovis AB’s Antibody Tools. These innovative research tools simplify procedures which, until now, have often yielded unpredictable and inconsistent results. Genovis AB’s Antibody Tools eliminate these problems, and we are grateful for the opportunity to present these products to our customers, says Dr Eileen Skaletsky